Does Medicare Cover Wegovy?

🔑 10 Key Takeaways

Medicare still bans weight-loss-only drug coverage by federal law. The Part D statute excludes drugs prescribed solely for weight loss — and that hasn’t changed in 2026.

Wegovy is covered right now for heart disease patients. If you have documented cardiovascular disease plus obesity or overweight, Medicare Part D can cover Wegovy for cardiovascular risk reduction — not weight loss.

A $50/month Medicare demonstration program launches July 2026. Eligible Medicare Part D beneficiaries will access GLP-1 medications for just $50 per month through a new CMS payment demonstration.

The full BALANCE model starts January 2027 for Medicare Part D. This voluntary CMS model will negotiate prices directly with manufacturers and waive the Part D weight-loss exclusion for participating plans.

Medicare’s negotiated GLP-1 price is $245/month. The government will pay $245 per month for Ozempic, Wegovy, Mounjaro, and Zepbound — less than half what the Biden administration proposed.

Ozempic is covered for type 2 diabetes, not weight loss. Medicare Part D covers Ozempic when prescribed for blood sugar control in type 2 diabetes patients. Prescribing it off-label for weight loss remains excluded.

The Wegovy pill launched January 2026 at $149/month self-pay. The first oral GLP-1 for weight loss — no injections, no refrigeration — is now available at a fraction of the injectable cost.

Only 13 state Medicaid programs cover GLP-1s for obesity. Four states (California, New Hampshire, Pennsylvania, South Carolina) eliminated Medicaid obesity drug coverage since October 2025 due to budget pressures.

Zepbound has a separate coverage pathway through sleep apnea. If you have moderate-to-severe obstructive sleep apnea with obesity, Medicare Part D may cover Zepbound — even without heart disease.

Over 80% of Medicare prior authorization appeals succeed. Yet only about 11% of denied patients ever appeal. If you’re denied Wegovy coverage, the odds are overwhelmingly in your favor if you fight back.

---

Federal Law Still Blocks Medicare from Covering Weight-Loss Drugs — Here’s the Exact Statute That’s Causing All the Confusion

Here’s the uncomfortable truth that most articles dance around: Section 1927(d)(2) of the Social Security Act explicitly allows Medicare Part D to exclude “agents when used for anorexia, weight loss, or weight gain.” This provision has been in place since the Part D program launched in 2006, and no administration — Obama, Trump (first term), Biden, or Trump (second term) — has managed to get Congress to repeal it.

The Biden administration attempted a workaround in November 2024 by proposing to reinterpret this exclusion so it wouldn’t apply to drugs treating obesity as a chronic disease. The Congressional Budget Office estimated that change would cost Medicare roughly $35 billion over a decade. On April 4, 2025, CMS released its Contract Year 2026 final rule and officially declined to include that reinterpretation.

So the law stands. But that doesn’t mean Medicare beneficiaries are locked out. The current administration found a different path — negotiating directly with manufacturers to lower prices enough that coverage could expand through demonstration authority rather than statutory change.

📋 The Legal Landscape	📌 Status in 2026
⚖️ Federal law banning weight-loss drug coverage	Still in effect — unchanged
🔄 Biden’s proposed reinterpretation	Rejected in April 2025 final rule
💊 Wegovy for cardiovascular risk reduction	Covered under Part D (since March 2024 FDA approval)
💊 Zepbound for obstructive sleep apnea	Covered under Part D (since December 2024 FDA approval)
💊 Ozempic for type 2 diabetes	Covered under Part D
🏥 GLP-1 payment demonstration	Launches July 2026 — covers obesity for first time
📊 BALANCE model (full Medicare Part D)	Launches January 2027

---

Yes, Wegovy Is Covered by Medicare Right Now — But Only Through the Cardiovascular Backdoor

This is the single most important pathway available to Medicare beneficiaries today, and it’s wildly underutilized.

On March 8, 2024, the FDA expanded Wegovy’s approved uses to include reducing the risk of major adverse cardiovascular events — specifically heart attack, stroke, and cardiovascular death — in adults with established cardiovascular disease who are overweight or obese. This approval was based on the landmark SELECT trial, which enrolled 17,604 participants and demonstrated that semaglutide 2.4 mg reduced MACE events by 20% compared to placebo over nearly 40 months of follow-up.

Because this indication treats cardiovascular disease rather than obesity per se, it falls outside the statutory weight-loss exclusion. CMS issued guidance confirming that Part D plans can add Wegovy to their formularies for this specific use.

To qualify through this pathway right now, you typically need all three of these:

One, established cardiovascular disease — meaning a prior heart attack, prior stroke, or documented peripheral arterial disease. Two, a BMI of 27 or higher. Three, your prescribing physician must code the prescription with a cardiovascular diagnosis code (like I25.10 for coronary artery disease), not an obesity code.

The critical nuance: your doctor cannot prescribe Wegovy and list “weight loss” or “obesity” as the primary reason. The prescription must document cardiovascular risk reduction as the clinical purpose. Same drug, same patient, same outcome — but the paperwork determines whether Medicare pays.

An estimated 3.6 million Medicare beneficiaries had both established cardiovascular disease and obesity or overweight based on KFF analysis. That’s roughly 1 in 4 Medicare beneficiaries with obesity who could be eligible through this pathway right now. Yet adoption remains low, largely because many physicians and patients don’t realize the coverage pathway exists.

---

No, Medicare Part B Does Not Cover Wegovy — And Probably Never Will

This question comes up constantly, and the answer is straightforward. Medicare Part B covers drugs administered by healthcare providers in clinical settings — think infusions, injections given in a doctor’s office, or chemotherapy. Wegovy is a self-administered injection (or now a self-administered pill) that patients take at home. Self-administered drugs fall under Part D, not Part B.

There is no current pathway, proposed pathway, or realistic future pathway for Wegovy coverage under Medicare Part B. If someone tells you otherwise, they’re confusing Part B with Part D.

💊 Medicare Part	What It Covers	Wegovy Status
🅰️ Part A	Hospital stays, skilled nursing	❌ Not applicable
🅱️ Part B	Doctor-administered drugs, outpatient care	❌ Does not cover Wegovy
🆎 Part C (Advantage)	Bundles A + B + usually D through private plans	✅ May cover via Part D component
🅳 Part D	Self-administered prescription drugs	✅ Covers Wegovy for CV risk reduction; obesity coverage coming July 2026

---

Medicare Will Cover Weight-Loss Drugs Starting July 2026 — Here’s Exactly How the $50 Copay Program Works

The single biggest development in Medicare weight-loss coverage history is arriving this summer. CMS announced a Medicare GLP-1 payment demonstration launching in July 2026 that will, for the first time, allow Medicare beneficiaries to access GLP-1 medications for obesity treatment — not just diabetes or cardiovascular disease.

Here’s how it works mechanically. This demonstration operates completely outside the standard Part D benefit structure. Part D plan sponsors carry zero financial risk for GLP-1 drugs furnished under the demonstration — CMS administers the entire program. That’s crucial because it means the statutory Part D weight-loss exclusion is effectively bypassed through demonstration authority rather than a change in law.

Eligible Medicare beneficiaries enrolled in Part D will pay $50 per month for their GLP-1 medication. The government’s negotiated cost is $245 per month — secured through Most Favored Nation pricing agreements with Eli Lilly and Novo Nordisk announced in November 2025.

The phased eligibility rollout will likely look like this based on the administration’s announcements:

Phase 1 covers overweight individuals with a BMI greater than 27 who also have prediabetes or diagnosed cardiovascular disease. Phase 2 expands to individuals with a BMI over 30 who have uncontrolled hypertension, kidney disease, or heart failure. Beneficiaries seeking Wegovy for weight loss alone without a qualifying health condition will not be eligible.

🗓️ Timeline	📌 What Happens
🔵 Now (February 2026)	Wegovy covered via CV indication only; details of July demonstration pending
🟡 May 2026	BALANCE model opens for state Medicaid programs
🟢 July 2026	Medicare GLP-1 payment demonstration launches — $50/month copay
🔵 October 15 – December 7, 2026	Annual Enrollment Period — Part D plans may begin incorporating GLP-1 coverage
🟣 January 2027	Full BALANCE model launches for Medicare Part D plans
🔴 December 2031	Model testing period ends

---

Yes, Medicare Covers Ozempic — But Exclusively for Type 2 Diabetes, Not Weight Loss or Prediabetes

Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) carries FDA approval specifically for improving glycemic control in adults with type 2 diabetes. Medicare Part D has covered Ozempic for this indication since the drug’s approval in 2017. If your doctor prescribes Ozempic with a type 2 diabetes diagnosis code, and it’s on your plan’s formulary, your Part D plan will typically cover it after applicable deductibles and cost-sharing.

However, two critical distinctions trip people up constantly.

Ozempic for prediabetes: No. Ozempic is not FDA-approved for prediabetes, and Medicare does not cover off-label prescribing for this purpose. Despite the fact that two-thirds of participants in the SELECT trial met criteria for prediabetes, and the data strongly suggests cardiovascular and metabolic benefits in that population, there is currently no approved indication and no coverage pathway for prediabetes alone.

Ozempic for weight loss: Absolutely not under Medicare. Even though Ozempic and Wegovy contain the same active ingredient (semaglutide), they’re approved for different uses at different doses. Prescribing Ozempic off-label for weight loss falls squarely within the Part D statutory exclusion. Some physicians do prescribe Ozempic off-label for weight loss in non-Medicare populations, but doing so for a Medicare patient and expecting Part D coverage is a non-starter.

---

The Wegovy Pill Changes Everything — $149/Month Without Insurance, No Refrigeration, No Needles

On December 22, 2025, the FDA approved oral semaglutide 25 mg — branded as the Wegovy pill — making it the first oral GLP-1 medication approved for weight loss and cardiovascular risk reduction in the United States. Novo Nordisk launched it in U.S. pharmacies in early January 2026.

The clinical data from the OASIS 4 trial demonstrated 16.6% mean body weight loss at 64 weeks when patients adhered to the full treatment course (13.6% in the broader intent-to-treat analysis). One-third of participants achieved 20% or greater weight loss. Those numbers are essentially equivalent to the injectable Wegovy 2.4 mg results.

For self-pay patients, the pricing structure is dramatically different from the injectable:

💊 Wegovy Form	💰 Self-Pay Price (2026)	🏥 Medicare Copay (July 2026+)	📋 Notes
💉 Injectable 0.25 mg & 0.5 mg (starting doses)	$199/month (limited-time through March 2026), then $349/month	$50/month (demonstration)	Requires refrigeration
💉 Injectable 2.4 mg (maintenance)	~$350/month via TrumpRx	$50/month (demonstration)	Weekly injection
💊 Pill 1.5 mg (starting dose)	$149/month	$50/month (when added to demonstration)	No refrigeration needed
💊 Pill 25 mg (maintenance dose)	$199–$299/month	$50/month (when added to demonstration)	Must wait 30 min before eating

The pill is manufactured at Novo Nordisk’s North Carolina facility, and robust supply is reportedly on hand. The oral formulation doesn’t require refrigeration, making it considerably more practical for seniors who travel or lack reliable cold storage.

---

How Much Wegovy Actually Costs with Medicare — The Real Numbers Behind the Copay

Let’s break down the actual dollar amounts a Medicare beneficiary will face depending on their coverage pathway, because the math matters more than the headlines.

Pathway 1 — Current cardiovascular indication (available now):

Your Part D plan’s standard cost-sharing applies. In 2026, the Part D annual deductible is $615. After meeting that deductible, you typically pay 25% coinsurance until you reach the $2,100 annual out-of-pocket maximum. Once you hit $2,100, Medicare covers 100% of your drug costs for the rest of the year. At the negotiated net price of approximately $245/month, your total annual exposure would be capped at $2,100 — regardless of how many months you take the drug.

Pathway 2 — July 2026 GLP-1 demonstration program:

Flat $50/month copay. This operates outside the standard Part D benefit, meaning it doesn’t interact with your deductible or coverage phases. Twelve months of Wegovy would cost you $600 total out of pocket.

Pathway 3 — Self-pay through TrumpRx (anyone, including Medicare beneficiaries):

Important clarification: standard TrumpRx coupons are not available to Medicare or Medicaid enrollees. However, the separate Medicare pricing track negotiated alongside TrumpRx sets the $245 government cost and $50 beneficiary copay for the demonstration program. If you’re a Medicare beneficiary who cannot wait for July 2026 and doesn’t qualify through the cardiovascular pathway, your self-pay options include the Wegovy pill at $149/month (starting dose) through Novo Nordisk’s direct channels, or the injectable at $199–$349/month.

💰 What You’ll Pay	🩺 CV Pathway (Now)	🏛️ Demonstration (July 2026)	💳 Self-Pay
Monthly cost	~$50–$150 depending on plan phase	$50 flat	$149–$349
Annual deductible applies?	✅ Yes ($615)	❌ No	❌ No (cash)
Counts toward $2,100 cap?	✅ Yes	❌ Separate program	❌ No
Maximum annual cost	$2,100	$600	$1,788–$4,188

---

State-by-State: Where Medicaid Covers GLP-1s for Obesity — and Where States Are Pulling Coverage

While Medicare operates under uniform federal rules, Medicaid coverage varies wildly by state. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service — and that number is actually shrinking, not growing. Four states eliminated coverage since October 2025 due to budget crises.

Every state Medicaid program is required to cover GLP-1s when prescribed for type 2 diabetes (Ozempic, Mounjaro) and for cardiovascular risk reduction (Wegovy) and obstructive sleep apnea (Zepbound). The optional part is coverage specifically for obesity treatment.

🏛️ State Coverage Status (Jan 2026)	📋 States
✅ Cover GLP-1s for obesity (Medicaid FFS)	Massachusetts, Minnesota, Mississippi, Wisconsin, Michigan (restricted to morbid obesity only), Virginia, North Carolina (reinstated Dec 2025), Rhode Island, Kansas, New York, Delaware*, Texas (partial), Arizona (partial)
❌ Eliminated obesity coverage since Oct 2025	California (Jan 1, 2026), Pennsylvania (adults 21+, Jan 1, 2026), New Hampshire, South Carolina
🔄 Restricting coverage in 2026	Michigan (now requires morbid obesity + failed all other interventions + bariatric surgery alternative), Connecticut (proposed ending)
📊 Considering expansion	Approximately half of remaining states — but cost is the primary barrier cited by nearly two-thirds of state programs
🟡 BALANCE model Medicaid launch	May 2026 (voluntary opt-in by states)

Note: Delaware’s coverage is in flux — verify directly with your state Medicaid program.

The BALANCE model launching in May 2026 for Medicaid could reshape this map significantly. Under BALANCE, CMS negotiates standardized pricing and coverage terms directly with manufacturers, then states opt in voluntarily. The model waives the weight-loss coverage exclusion for participating programs and requires manufacturers to provide guaranteed rebates. But participation is voluntary at every level — manufacturers, states, and plans all choose whether to join.

---

North Dakota Made History — The First State to Mandate Private Insurance Coverage of GLP-1 Drugs

While Medicare and Medicaid dominate the coverage conversation, the private insurance landscape is evolving through state legislation. In January 2025, North Dakota became the first state in the nation to mandate that individual and group health plans cover GLP-1 and GIP medications by adding them to the state’s Essential Health Benefits benchmark plan under the Affordable Care Act.

During the first two quarters of 2025, at least 14 states introduced legislation or took regulatory action affecting GLP-1 coverage. Bills ranged from mandating private insurance coverage (West Virginia, Texas, Iowa) to requiring Medicaid expansion (Arkansas, Mississippi, Virginia). Most did not advance, but the legislative momentum signals a shift in how state lawmakers view obesity treatment.

🏛️ State Legislative Action (2025)	📋 Status
✅ North Dakota	First state to mandate private plan GLP-1 coverage (enacted)
📝 West Virginia HB 2912	Would require insurance coverage for GLP-1s with valid prescription
📝 Texas HB 2412	Would mandate GLP-1 coverage (did not advance)
📝 Iowa SSB 1138	Would require state agency review of GLP-1 as employee benefit
📝 Montana SB 417	Antiobesity medication mandate (did not advance)
📝 New Mexico SB 193	Antiobesity medication mandate (did not advance)
📝 Mississippi SB 2867	Medicaid GLP-1 coverage (passed legislature, vetoed by governor)

---

The GLP-1 Drugs Medicare Currently Covers — And What Each One Actually Treats

Not all GLP-1 medications are interchangeable, and Medicare treats them very differently depending on their FDA-approved indication. Here’s the complete breakdown:

💊 Drug	🏭 Manufacturer	✅ FDA-Approved Uses	🏥 Medicare Part D Coverage?
💉 Ozempic (semaglutide 0.5–2 mg)	Novo Nordisk	Type 2 diabetes; CV risk reduction in T2D	✅ Yes — for diabetes and CV risk
💉 Wegovy (semaglutide 2.4 mg injection)	Novo Nordisk	Obesity/overweight; CV risk reduction; MASH with liver fibrosis	✅ For CV risk reduction only (obesity coverage July 2026)
💊 Wegovy pill (semaglutide 25 mg oral)	Novo Nordisk	Obesity/overweight; CV risk reduction	✅ For CV risk reduction only (obesity coverage July 2026)
💉 Mounjaro (tirzepatide)	Eli Lilly	Type 2 diabetes	✅ Yes — for diabetes
💉 Zepbound (tirzepatide)	Eli Lilly	Obesity/overweight; moderate-severe OSA with obesity	✅ For OSA only (obesity coverage July 2026)
💊 Rybelsus (oral semaglutide 7–14 mg)	Novo Nordisk	Type 2 diabetes; CV risk reduction in T2D	✅ Yes — for diabetes and CV risk
💉 Saxenda (liraglutide 3 mg)	Novo Nordisk	Obesity/overweight	❌ Not covered (no non-obesity indication)
💉 Victoza (liraglutide 1.8 mg)	Novo Nordisk	Type 2 diabetes	✅ Yes — for diabetes

---

The Smart Patient’s Playbook: 7 Strategies to Get Wegovy Covered by Medicare Before July 2026

If you can’t wait until the demonstration program launches, here are the actual, tested approaches that work:

Strategy 1 — The cardiovascular indication pathway. If you have any documented history of heart attack, stroke, or peripheral arterial disease, ask your cardiologist or primary care physician to prescribe Wegovy specifically for cardiovascular risk reduction. The prescription must carry a cardiovascular ICD-10 diagnosis code, not an obesity code.

Strategy 2 — Request a formulary exception. If Wegovy isn’t on your plan’s drug list, you or your doctor can submit a non-formulary medical exception request. Novo Nordisk’s own patient support site recommends this approach for Medicare patients. Your doctor provides clinical documentation explaining why Wegovy is medically necessary for your non-weight-loss condition.

Strategy 3 — Appeal every denial. Over 80% of Medicare Advantage prior authorization appeals succeed, according to KFF analysis. Yet only about 11% of patients ever file an appeal. Request the Coverage Determination Notice with the specific denial reason. You have 60 days to appeal, and the process is straightforward.

Strategy 4 — Check the Zepbound sleep apnea pathway. If you have moderate-to-severe obstructive sleep apnea and obesity, Zepbound received FDA approval for this indication in December 2024. This creates a separate Part D coverage pathway that doesn’t require cardiovascular disease.

Strategy 5 — Consider the Wegovy pill at $149/month. If you’re paying entirely out of pocket, the new oral formulation is roughly 60–70% cheaper than the injectable was at its original list price. At $149/month for the starting dose, it may be affordable enough to bridge the gap until July.

Strategy 6 — Explore the Medicare Prescription Payment Plan. Launched in 2025, this program lets you spread your prescription drug costs into equal monthly payments rather than paying large amounts upfront at the pharmacy. Enroll through your Part D plan.

Strategy 7 — Document everything for July. Start building your medical file now. Weight history, prior weight management attempts (diet programs, exercise documentation, previous medications), comorbidity records, and BMI measurements. When the demonstration launches, having thorough documentation will speed your qualification process.

---

Why 52.5% of Patients Stop Semaglutide Within a Year — The Adherence Problem Nobody Wants to Talk About

Here’s a data point that most pro-GLP-1 coverage articles conveniently omit: CMS’s own actuarial office cites research showing that 52.5% of patients with overweight or obesity taking semaglutide discontinue treatment within one year. A separate survey of patients with type 2 diabetes who stopped GLP-1 therapy cited gastrointestinal side effects as the most common reason.

This has enormous policy implications. If half of patients stop within 12 months, the actual per-patient cost to Medicare is substantially lower than the theoretical annual cost — but it also means the health benefits may be temporary, since weight regain after GLP-1 discontinuation is well-documented.

The BALANCE model attempts to address this head-on by requiring participating manufacturers to provide “evidence-based lifestyle supports” alongside medication access. The idea is that combining pharmaceutical treatment with behavioral and nutritional interventions will improve long-term adherence and reduce regain — though CBO noted there isn’t yet strong empirical evidence for medical spending offsets from improved health.

📊 Adherence Reality Check	📌 Data Point
❌ Patients discontinuing semaglutide within 1 year	52.5% (CMS OACT estimate)
🤢 Top reason for stopping	Gastrointestinal side effects (nausea, vomiting, diarrhea)
⚖️ Weight regain after stopping	Significant — most studies show substantial regain within 1–2 years
💊 SELECT trial discontinuation rate	16.6% permanently stopped semaglutide vs 8.2% on placebo
🏃 BALANCE model requirement	Lifestyle support programs mandatory alongside medication

---

Compounded Semaglutide Is Gone — Why the Cheaper Alternative Disappeared in 2025

Many Medicare beneficiaries who couldn’t afford brand-name Wegovy turned to compounded versions of semaglutide that were available during the FDA-declared shortage. That window slammed shut. The FDA declared the Ozempic and Wegovy shortage resolved on February 21, 2025, and compounding pharmacies were required to stop producing semaglutide by April 22, 2025.

This leaves only brand-name options available in 2026. The silver lining is that between the Wegovy pill at $149/month, TrumpRx pricing at $199–$350/month for injectables, and the upcoming $50/month Medicare demonstration, brand-name access is actually more affordable now than compounded versions were for many patients.

---

Frequently Asked Questions

Can I use TrumpRx to buy Wegovy if I’m on Medicare?

The TrumpRx coupons and direct-to-consumer discounts are not available to Medicare or Medicaid enrollees — you must attest that you’re paying cash without government insurance. However, the same pricing negotiations that created TrumpRx also established the separate $245/month Medicare price and $50/month beneficiary copay coming in July 2026. These are administered through your Part D plan, not through the TrumpRx website.

Will semaglutide be selected for Medicare drug price negotiation?

Possibly as early as 2025 for implementation in 2027. Semaglutide (via Ozempic’s December 2017 approval) meets the seven-year threshold for small-molecule drugs under the Inflation Reduction Act negotiation provisions. CBO modeling has already incorporated the potential for negotiated semaglutide prices to drop significantly in 2027.

Does Medicare cover Wegovy for MASH (liver disease)?

The injectable Wegovy received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. This is another non-obesity indication that could create a Part D coverage pathway, though plan formulary inclusion will vary.

What if my doctor prescribes Ozempic “off-label” for weight loss — will Medicare catch it?

Part D plans adjudicate claims based on diagnosis codes and approved indications. If your prescription carries a weight-loss or obesity diagnosis code, the claim will typically be rejected. Some physicians prescribe Ozempic with a type 2 diabetes code for patients who have both conditions, which is clinically appropriate when diabetes is genuinely present. Coding an obesity-only patient as diabetic to obtain coverage would constitute fraud.

How long do I need to be on Wegovy for Medicare to keep covering it?

There is no set duration limit under the current cardiovascular indication pathway. However, prior authorization renewals are typically required every 6–12 months, and your plan may require documentation that the medication continues to provide cardiovascular benefit. Under the July 2026 demonstration program, coverage criteria and duration rules are still being finalized.

Is there an age limit for Wegovy under Medicare?

No. The FDA approval has no upper age limit, and Medicare doesn’t impose one. The SELECT trial included participants aged 45 and older with a mean age of 61.6 years. However, your physician should evaluate your individual risk-benefit profile, particularly if you have advanced age-related conditions that might increase susceptibility to side effects like nausea, dehydration, or muscle mass loss.

My Medicare Advantage plan denied Wegovy — what exactly do I do?

First, request the Coverage Determination Notice in writing with the specific reason for denial. Then file a Level 1 appeal (redetermination) with your plan, including your doctor’s clinical documentation supporting the cardiovascular indication. Your plan must respond within 7 days for standard appeals or 72 hours for expedited requests. If denied again, escalate to a Level 2 appeal with an Independent Review Entity. Remember: over 80% of MA prior authorization appeals ultimately succeed.

Will the Wegovy pill be covered the same as the injection under Medicare?

The Wegovy pill carries the same FDA-approved indications as the injection — both weight management and cardiovascular risk reduction. It should qualify for the same Part D coverage pathways. When the July 2026 demonstration launches, both forms are expected to be included at the same $50/month copay, though final details haven’t been published yet.